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While many neuroprotectants have been tested in animal stroke models, none have yet proven to be safe, well-tolerated, and effective in clinical trials of acute ischemic stroke. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Repinotan is a potent full agonist at the serotonin (5-HT 1A ) receptor. 15 In animal models, repinotan demonstrated neuroprotectant activity over a broad range of doses for up to five hours postischemia [15] [16] [17] and was well-tolerated with no safety concerns in healthy volunteers. 18 The primary objective of this phase II Bayer Randomized Acute Ischemia Neuroprotectant Study (BRAINS) was to evaluate the safety and tolerability of three doses of intravenous repinotan in patients with acute ischemic stroke.
METHODS
This was a multicenter, randomized, double-blind, placebocontrolled study of the safety and tolerability of repinotan in patients with acute ischemic stroke. The study was carried out in accordance with United States and Canadian regulatory requirements and in accordance with International Conference on Harmonization -Good Clinical Practice Guidelines. The study protocol was approved by an appropriate Institutional Review Board at each study site. Patients or their legally authorized representatives gave written informed consent before initiation of treatment.
An independent Safety Monitoring Committee (SMC) was established prior to the start of the study. The SMC reviewed data in a blinded manner after treatment of 25%, 50%, and 100% of patients, and serious adverse events were reported to the chairman of the SMC.
Patient Population
Patients with a suspected stroke consistent with acute cerebral hemispheric ischemia of thromboembolic origin were recruited from 31 university and community medical centers in Canada and the United States. Patients were required to be at least 18 years old with a neurological deficit, no signs of improvement for a minimum of one hour, and a National Institutes of Health Stroke Scale (NIH-SS) 19 total score of 4 to 25 with a motor deficit ≥ 2 and a level of consciousness < 2.
Patients were excluded if there was intracerebral hemorrhage on computed tomography (CT) scan, if any finding was inconsistent with an acute ischemic hemispheric stroke, or if the stroke involved the posterior circulation (the brain stem or cerebellum). Patients were ineligible if any other neurological or psychiatric condition was present that possibly would affect functional status, including a previous stroke with significant residual deficit. Patients with severe cardiovascular problems and those with significant hepatic, renal, or other clinically significant disease states were not candidates. Patients were not permitted to receive t-PA during the study.
Baseline Evaluations
All patients underwent a baseline assessment, which included a complete history and physical examination, vital signs assessment, 12-lead electrocardiogram (ECG), chest radiograph (if clinically indicated), complete neurological examination, and CT scan. The NIH-SS and a historical Rankin Scale 20 were performed and blood was drawn.
Study Treatment
Eligible patients were randomized to repinotan 0.5, 1.25, 2.5 mg/d or placebo. Randomization was accomplished with a c o m p u t e r-generated list provided by the study sponsor. Sequential numbers in blocks of four were provided to each study center. Repinotan was supplied as lyophilized powder in vials containing 0.4, 1.0 and 2 mg of active drug and was stored at room temperature and protected from light. Immediately prior to use, repinotan was reconstituted with 100 mL normal saline. The reconstituted solution was stable for 24 hours at room temperature. Study drugs were given for 72 hours by continuous intravenous infusion (5.2 mL/hour) starting no later than six hours after the onset of stroke symptoms. All standard therapies used in the management of acute stroke patients were allowed at the discretion of the investigator with the exception of prohibited medications. Physical, occupational, and speech therapies were initiated as appropriate. The co-administration of serotonin receptor agonists or antagonists, selective serotonin reuptake inhibitors or monoamine oxidase inhibitors, and medications known to interact with the cytochrome P450 2D6 (CYP2D6) pathway were prohibited during study drug infusion and for 24 hours postinfusion. Repinotan is metabolized by cytochrome P450 2D6; to detect patients who were poor metabolizers, venous blood samples were collected at six and 10 hours to measure plasma repinotan levels. The sample was immediately analyzed by an enzyme-linked immuno-absorbent assay (ELISA). The study investigator was blind to the ELISA results unless the plasma repinotan level was above 15 ng/mL, in which case the investigator was notified and the repinotan infusion was discontinued to avoid possible further drug accumulation. All patients were followed according to protocol, regardless of the duration of therapy.
Study Assessments
Patients were monitored closely and assessed daily in a stroke unit or intensive care unit for the duration of study drug treatment and up to 24 hours following its completion. Safety and efficacy assessments were completed at four weeks and three months poststroke. The primary safety parameters were mortality, premature termination from study participation, and adverse events defined by COSTART (an international coding system for adverse drug events) according to intensity, severity, and relationship (assessed continuously to discharge and then at four weeks and three months). Changes in laboratory findings (24h, 96h, four weeks), vital signs (every (q)15min x 1h, q1h x 24h, then q4h until 96h), 12-lead ECG (24h, 96h, four weeks), and neurological findings (q2h x 12h, q4h x 12h, then q8h until 96h) were also noted. Serious adverse events were defined as those events that were life threatening, disabling, or resulted in hospitalization or prolongation of hospitalization and occurring during or within seven days of study completion. Deaths occurring within 30 days after the last visit were also included. The NIH-SS was used to assess neurological recovery and was performed by a neurologist certified in its administration according to standard published guidelines. Functional improvement was assessed with the Barthel Index 21 and the modified Rankin Scale.
Patient Withdrawals
Patients were withdrawn from the study if an adverse event or THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES laboratory abnormality was considered clinically significant, an adverse event was serious, there was noncompliance with the protocol, or the plasma level of repinotan was >15 ng/mL. These patients were excluded from the prespecified per-p r o t o c o l analysis but follow-up was continued. Any patient who discontinued prior to completion of drug administration was defined as a premature withdrawal and was followed to the threemonth poststroke visit. If a patient was removed due to an adverse event, follow-up was according to established, acceptable medical practice until resolution of the event or study completion.
Statistical Methods
All patients randomized to treatment and who met all the inclusion criteria were included in the intent-to-treat (ITT) population. Data were analyzed by the study sponsor using a Statistical Analysis System package. Baseline characteristics and changes in laboratory values, vitals signs, neurological assessments, and ECG were summarized with descriptive statistics. Success rates were assessed with the NIH-SS, Barthel Index, and modified Rankin Scale. A successful response was defined as a 4-point improvement from baseline or a return to normal (0-1) on the NIH-SS, a score of 85 to 100 on the Barthel Index, or a score of 0 or 1 on the modified Rankin scale. Success rates were compared between treatment groups with the MantelHaenszel test and summarized using relative risk and 95% confidence interval (CI). The 30-day mortality rate and 95% CI were determined. All statistical tests were two-sided at the α = 0.05 level.
RESULTS
The ITT analysis included 240 patients who were randomized and received at least part of the study drug infusion. Of these, 50 patients (20.8%) withdrew from the study prematurely, including 36 who withdrew after hospital discharge (Table 1 and Figure) . The per protocol population comprised 187 patients who completed the treatment protocol with no major protocol violations. Of the 53 patients excluded from the per-protocol analysis, 34 were ELISA-positive. At baseline, no important d i fferences were observed between treatment groups for demographic characteristics, including mean age, mean NIH-SS score, and prior history ( Table 2) . Compared with the placebo group, patients in the repinotan-treated groups were more likely to have a history of prior neurological disability, prior strokes, and prior transient ischemic attacks.
Adverse Events
At least one treatment-emergent adverse event occurred in 224 (93.3%) patients (Table 3 ). The most commonly reported adverse event was headache, ranging in incidence from 21. 35.0% with repinotan and 24.1% in the placebo group. Most adverse events were of mild or moderate severity; 59 (25%) patients reported at least one severe adverse event. The most common severe adverse events were neurological worsening, cerebral hemorrhage, and brain edema. Thirteen patients discontinued treatment for adverse events (Table 4) . Most were considered either remotely related or unrelated to study treatment.
Safety Evaluations
Of 46 (19.2%) patients who died, 43 died within 30 days of the end of the repinotan infusion and three died beyond 30 days. Mortality rates were 22.4% in the placebo group, 14.8% in the 0.5 mg/d group, 21.3% in the 1.25 mg/d group, and 18.3% in the 2.5 mg/d group. The cause of death was most commonly reported as cerebral edema/herniation or cardiac, including cardiopulmonary arrest, myocardial infarction, and congestive heart failure. Respiratory failure, recurrent stroke, progression of stroke, pneumonia, and sepsis were also reported as causes of death. No differences across treatment groups were noted in the types of events reported as the cause of death. For most laboratory parameters, changes from baseline were small and not clinically relevant. Liver function tests that were ≥3 times the upper limit of normal were reported in five patients in the repinotan 2.5 mg/d group, three in the 1.25 mg/d group, and one each in the 0.5 mg/d and placebo groups.
Fluctuations in systolic and diastolic blood pressure were observed across all treatment groups and ranged between -3.4 and -11.4 mm Hg, but there were no clinically relevant differences among the groups. Mean changes from baseline in heart rate ranged from 0 to -5 beats/minute and were similar across the treatment groups at each time point. Mean changes in ECG P-R, QRS, and Q-T intervals at the 24-and 96-hour time points approximated 0 for all treatment groups with no differences among the groups.
Outcome Assessments
No significant differences were observed in relative risk (95% CI) of treatment failure between any dose of repinotan and placebo at either four weeks or three months ( Table 5 ). The highest NIH-SS success rates at four weeks and three months were seen in the 0.5 mg/d and 1.25 mg/d repinotan dose groups (Table 5) . A trend toward improvement on the NIH-SS at three months was observed for all active treatment groups relative to placebo. The highest Barthel Index success rates at the four-week and three-month evaluations were observed in the 1.25 mg/d repinotan dose group (Table 5 ). The success rates for the modified Rankin scale at the four-week and three-month evaluations were lower in all repinotan treatment groups compared with the placebo group (Table 5) . However, the best outcome was observed at the repinotan 1.25 mg/d dose.
DISCUSSION
The primary objective of this study was to investigate the tolerability and safety of three doses of repinotan administered as a continuous infusion over 72 hours in patients within six hours of onset of symptoms of an acute ischemic stroke. All treatment groups were comparable at baseline for severity of stroke. The placebo group had the lowest rate of previous transient ischemic attack or stroke and previous stroke disability, which may have affected outcomes. This imbalance may have been due to chance or possibly have resulted from the randomization procedure. Patients were excluded from participation if they received t-PA, because its use for acute stroke was investigational in Canada at the time of this study. This may have affected the selection of patients for inclusion in the study as few patients were treated within the first three hours of symptom onset. The mean time to treatment was 5.0 ± 0.9 hours, and this late treatment may have diminished efficacy signals.
Because this study was not powered to establish efficacy, signals of efficacy must be interpreted cautiously as exploratory data; however, the results from the ITT analysis suggest that repinotan may improve functional and neurological outcomes at three months. Although no significant differences were observed, the highest success rates were observed with the 1.25 mg/d dose of repinotan. One explanation for the lack of significant improvement with repinotan was the higher than expected placebo success rates on all three assessment scales. 22 The relatively modest and nonsignificant differences in outcome between placebo and repinotan groups may be attributed to a number of factors, including a sample size designed to evaluate safety rather than efficacy, patient selection criteria, and a late mean time to treatment. [22] [23] [24] A recently initiated study of IV magnesium for acute stroke estimated that 2700 patients were required to detect a 5.5% absolute difference between active treatment and placebo. 25 A post hoc analysis from a recent failed trial of citicoline observed greater absolute difference in outcomes between active treatment and placebo groups when patients with mild strokes were excluded. 4 In conclusion, repinotan was safe and well-tolerated in this population of stroke patients. Compared with placebo, repinotan exhibited an acceptable tolerability profile with adverse events that mostly related to known serotonergic activity. The results suggest that the 1.25 mg/d dose of repinotan offers a balance of pharmacologic effect and tolerability. The future development of repinotan for acute ischemic stroke will require larger studies to evaluate efficacy.A phase IIb trial of approximately 700 patients will be completed in 2004. 
